---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-035245"
form_type: "8-K"
ticker: "VTAK"
cik: "0001716621"
company_name: "Catheter Precision, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:52:57.716113+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Catheter Precision Q3 revenue up 135% to $226K; net loss down 45% to $2.25M

## Summary
- Total revenue Q3 2025: $226K, +135% YoY from $96K; nine-month revenue $581K, +114%.
- GAAP net loss Q3 2025: $2.25M, 45% reduction from $4.12M in Q3 2024.
- Nine-month net loss $11.4M vs $11.0M; non-cash charges $4.2M.
- CE Mark approval for LockeT driving international interest; reorders in South Africa and first French VIVO order.
- VIVO clinical studies completed in 2025; CEO expects major US and international expansion.

## SEC filing metadata
- accession: 0001437749-25-035245
- form_type: 8-K
- ticker: VTAK
- cik: 0001716621
- company_name: Catheter Precision, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716621/000143774925035245/0001437749-25-035245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716621/000143774925035245/vtak20251113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-035245
- JSON: https://secwatch.observer/filing/0001437749-25-035245.json
- Plain text: https://secwatch.observer/filing/0001437749-25-035245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.